支气管动脉化疗栓塞联合康艾对中晚期肺癌转化治疗的临床疗效  

Clinical effect of bronchial artery chemoembolization combined with Kangai in conversion treatment of advanced lung cancer

作　　者：邢辉[1] 刘荣[1] 崔新江[1] 曹桂文[1] 于志军[1] XING Hui;LIU Rong;CUI Xinjiang;CAO Guiwen;YU Zhijun(Center of Intervention and Vascular Surgery,Affiliated Hospital of Weifang Medical University,Weifang 261041,China)

机构地区：[1]潍坊医学院附属医院介入血管外科中心,山东潍坊261041

出　　处：《医学影像学杂志》2023年第8期1382-1385,共4页Journal of Medical Imaging

基　　金：北京医卫健康公益基金会医学科学研究基金资助项目(编号:YWJKJJHKYJJ-F1144A)。

摘　　要：目的探讨通过支气管动脉灌注化疗栓塞联合康艾注射液对初始不可切除的Ⅲ期中央型非小细胞肺癌(non-small cell lung cancer,NSCLC)患者转化为根治性手术切除的临床疗效。方法选取中央型NSCLC患者36例,经支气管镜活检或经皮肺穿刺活检明确病理类型;通过颈胸部增强CT、头颅MRI、骨扫描和腹部CT检查进行临床评估及分期,确认为不可切除的Ⅲ期中央型NSCLC。36例患者均采用支气管动脉灌注化疗栓塞联合康艾注射液治疗,治疗两周期后评估能否手术切除。比较手术切除患者和不能手术切除患者的生存率和中位生存期。结果36例初始不可切除的Ⅲ期中央型NSCLC患者经过支气管动脉灌注化疗栓塞联合康艾注射液治疗后,其中可行根治性手术切除23例患者,术后给予辅助静脉化疗,不能手术切除13例继续给予静脉化疗或放疗。23例手术切除患者的中位生存期为31.2个月,1,2,3年生存率分别为78.2%、69.5%和56.5%。13例不能切除患者的中位生存期为15.6月,1,2,3年生存率分别为61.5%、38.5%和23.1%。结论通过支气管动脉化疗栓塞联合康艾注射液对初始不可切除的Ⅲ期中央型NSCLC患者转化为根治性手术切除取得了良好的临床疗效,值得大力推广。Objective To investigate the clinical efficacy of bronchial artery infusion chemoembolization combined with Kang'ai injection in the treatment of initially unresectable stageⅢcentral non-small cell lung cancer(NSCLC)patients converted to radical resection.Methods Thirty-six patients with central NSCLC underwent transbronchial or percutaneous lung biopsy to confirm the pathological type.The patient was diagnosed as unresectable stageⅢcentral NSCLC by neck and chest enhanced CT,head MRI,bone scan and abdominal CT.All 36 patients were treated with bronchial artery infusion chemoembolization combined with Kang'ai injection,and the surgical resection was evaluated after two cycles of treatment.The survival rate and median survival time of patients with surgical resection and unresectable were compared.Results A total of 36 patients with initially unresectable stageⅢcentral NSCLC were treated with bronchial artery chemoembolization combined with Kang'ai injection.Among them,23 patients who underwent radical resection were treated with adjuvant intravenous chemotherapy,and 13 patients who could not be surgically resected were treated with intravenous chemotherapy or radiotherapy.Among them,23 patients underwent radical surgical resection,and the median survival time of patients with surgical resection was 31.2 months.The 3-year survival rates were 78.2%,69.5%and 56%.The median survival time of the 13 unresectable patients was 15.6 months,and the 1-,2-,and 3-year survival rates were 61.5%,38.5%,and 23.1%.Conclusion Bronchial artery chemoembolization combined with Kang'ai injection has achieved good clinical efficacy in the conversion of initially unresectable stageⅢcentral NSCLC patients to radical resection,which is worthy of promotion.

关 键 词：支气管动脉 化疗栓塞 中晚期肺癌 康艾注射液 根治性手术 介入性 放射学 

分 类 号：R734.2[医药卫生—肿瘤] R815[医药卫生—临床医学]